NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Earnings for NovoCure Limited (NVCR)
Earnings in 2023 (TTM): $-191,740,000
According to NovoCure Limited's latest financial reports the company's current earnings (TTM) are $-191,740,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of NovoCure Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-191,740,000 | $-207,043,000 |
| 2022 | $-81,846,000 | $-92,534,000 |
| 2021 | $-52,075,000 | $-58,351,000 |
| 2020 | $18.1 M | $19.81 M |
| 2019 | $-8,824,000 | $-7,230,000 |
| 2018 | $-45,942,000 | $-63,559,000 |
| 2017 | $-48,497,000 | $-61,662,000 |
| 2016 | $-121,464,000 | $-131,845,000 |
| 2015 | $-107,147,000 | $-111,581,000 |
| 2014 | $-80,300,000 | $-80,682,000 |
| 2013 | $-77,017,000 | $-77,370,000 |